Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1799 results
August 2015
-
Media ReleaseNovartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leadersThe International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities The interactive program brought 70 university students…
-
Media ReleaseFDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopeniaNew oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…
-
Media ReleaseNovartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indicationsNovartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a…
-
Media ReleaseNovartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patientsApproval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is…
-
Media ReleaseNovartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 millionCSL Limited acquired influenza vaccines business of Novartis, including influenza vaccines development pipeline Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed…
July 2015
-
Story Discovery
Turning research advances into innovative medicinesA strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines
-
Media ReleaseNovartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group LtdNovartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds…
-
Media ReleaseNovartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg ReinhardtDr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School…
-
Media ReleaseFDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancerApproval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin…
-
Media ReleaseNovartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestonesCHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…
-
Media ReleaseNovartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorderIf approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA Approximately 40% of SAA patients unresponsive to initial immunosuppressive…
-
Story From Our Labs
Five things to look for in a scientific mentor